Edaravone may exert its neuroprotective effects in ALS by also correcting the abnormal localization of TDP-43, a key ...
12h
Stocktwits on MSNSarepta Therapeutics Temporarily Halts Three Clinical Studies Of Elevidys: Retail Is Dull While Stock DropsShares of Sarepta Therapeutics, Inc. (SRPT) traded over 2% lower in afternoon trade on Friday after the company said it has ...
The major workforce overhaul comes a month after parent company Roche deemed the cell and gene therapy firm a financial loss.
Roche’s reorganization of Spark Therapeutics is coming more into focus, with nearly 300 employees being let go by the end of ...
Artis BioSolutions joins a host of startups trying to improve development and manufacturing capacity for cutting-edge gene ...
Sarepta Therapeutics said on Friday it had temporarily halted three trials testing its gene therapy Elevidys, following the death of a patient last month upon receiving the treatment.
Explore more
If you look closely at the fundamental discoveries that have changed human health, physician–scientists have been at the ...
Gene therapy and gene editing are on the cutting edge of modern biotechnology. Gene therapies are used to correct genetic abnormalities by introducing genetic material at a cellular level and ...
Knocking out a single gene reprograms part of the large intestine to function like the nutrient-absorbing small intestine.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved ...
Sangamo Therapeutics has stacked up $18 million cash from Eli Lilly in a licensing deal that will let the pharma use the ...
Governor Gavin Newsom announced March 21 that the Department of Health Care Services submitted an application to the federal Center for Medicaid and Medicaid Innovation at the Centers for Medicare & ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results